To test the importance of RAC1 for drug resistance, we knocked down RAC1 in a panel of nine BRAFV600E cutaneous melanoma cell lines and assessed their growth in the presence or absence of a targeted inhibitor of BRAFV600E, vemurafenib (VEM). This evidence concerns the gene RAC1 and cutaneous melanoma.